All News

rare

ICYMI: Here at Last: Treatment Options for VEXAS

Michael Putman, MD, MSCI

We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.

Read Article
female with hands

ICYMI: Are Rheumatologists doing Enough for Cervical Cancer?

Eric Dein, MD

Should rheumatologists be counseling patients on cervical cancer prevention and screening?

Read Article
Stills,continuum

ICYMI: New Biomarkers and Therapeutics Show Potential in Still's Disease

Bella Mehta, MBBS, MS

Adult-onset Still’s disease is a rare complex, sporadic, systemic autoinflammatory disease similar to systemic juvenile idiopathic arthritis characterized by sustained fever, salmon-colored rash, and arthritis. The 2023 ACR convergence featured several abstracts spotlighting developments in understanding and managing this complex disease spectrum.

Read Article
multiple traffic lights

When should we be starting therapy in GCA and PMR?

David Liew, FRACP

The problem with having therapies that work is that you then have to figure out what to do with them. You cannot hide behind a shrug of the shoulders, or the ambiguity of therapeutic inadequacy. The question that follows the presence of a therapy is the question as to how to best use it.

GCA and PMR are at the stage in the growth of their therapeutic development where this problem is moving to the front of mind, and it made for a fitting topic in the ACR Great Debate. Drs. Rob Spiera and Phil Seo - two luminaries in the vasculitis and PMR worlds - were pitted head to head to discuss.

Read Article
- High mortality risk predictors in patients with anti-MDA5 dermatomyositis include: - rapidly progressive interstitial lung disease - anti-Ro52 antibody - age > 57 years (based on study of 126 MDA-5+ DM pts) https://t.co/8bw1zpEOIh https://t.co/LKXMYtr7hU

Links:

Dr. John Cush RheumNow ( View Tweet)
Empathy is the hard part. The rest is mechanics. We're not wired to walk in someone else's shoes, it's not our first instinct. Showing up with empathy is difficult, hard to outsource and will wear you out. But it's precisely what we need from you. - Seth Godin… https://t.co/U8Ou3WwBmC https://t.co/C4aAVovHDH
Dr. John Cush RheumNow ( View Tweet)
RHEUMATOLOGIST SURVEY QUESTION - Is TYK2 part of the Janus Kinase family? Click here to answer >> https://t.co/7SgvYqFe1W

Links:

Dr. John Cush RheumNow ( View Tweet)

Maryland specialty clinic eval 1395 Lyme pts & saw marked differences between blacks & whites. Black patients had 5 fold (OR 4.93) higher risk of disseminated LD & delay in Abx Rx. Dissem Dz also more likely in men (OR, 1.6) EM Rash harder to spot https://t.co/NL8yJ9CdvQ https://t.co/dUUXyWYbsT

Links:

Dr. John Cush RheumNow ( View Tweet)
Programmed-cell-death 1 (PD-1) expression on T-cells is assoc w/ activation & exhaustion. The exhausted phenotype of PD-1+CD8+ T cells add to the pathogenesis of active idiopathic inflammatory myositis. https://t.co/xOYfEs16ou https://t.co/MzEPpUc7Eb

Links:

Dr. John Cush RheumNow ( View Tweet)
Danish study compared 106K adults w/ major osteoporotic fracture (hip, vertebrae, wrist, humerus) vs 1+ mill controls & found Mortality highest 30d following 1st index hip Fx (HR 10.98 women; & HR 16.40 men). Pneumonia most common cause of mortality https://t.co/0D7ynN4f5L https://t.co/qX61cgq1SL

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiology 101 for the Rheumatologist Dr. Janet Pope reports on a cardiology session presented a 2023 ACR Convergence in San Diego, CA https://t.co/0cS8JVneIG https://t.co/6SIPx6WmqX

Links:

Dr. John Cush RheumNow ( View Tweet)
Subtype of dermatomyositis is positive for Melanoma differentiation-associated protein 5 (MDA5) antibody. This poor prognosis subtype has distinctive rashes, rapidly progressive interstitial lung disease, lymphopenia &elevated ferritin levels https://t.co/FJjdO27cQQ https://t.co/gis2aWOLa7

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Are Rheumatologists doing Enough for Cervical Cancer? https://t.co/afg5YL3RCN https://t.co/VRyKh6VgmS

Links:

Dr. John Cush RheumNow ( View Tweet)
According to AAMC, clinical neurophysiology has lowest (0.8) number of MDs/100K, while pediatrics has the highest (59.5). In a list of 52, Rheumatology is #17 at mean of 2 Rheums per 100,000 population https://t.co/BrrfSIeHb9 https://t.co/69kRSlk9Dq

Links:

Dr. John Cush RheumNow ( View Tweet)
Venous Thromboembolic Risk with Joint Replacement Save A recent study suggests that thromboprophylaxis strategies should be tailored to individual risk of thrombosis and bleeding. https://t.co/FKOsNkWMqz https://t.co/XH4SiQ735g

Links:

Dr. John Cush RheumNow ( View Tweet)
resolved HBV (HBsAg-, HBcAb+, HBsAb+) are at low risk of reactivation (~2%) w/ TNFi or biologics. But in a high risk endemic region (ie, Korea) this risk is higher. Study of 416 such pts HBV reactivation rate 3.5% @5 yrs, 6.1% @10 yrs & 24.2% @17 yrs https://t.co/oQ5e6O9wds https://t.co/50vBtapJVN

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of Hepatitis B reactivation is assessed by serology - Resolved HBV (low risk reactiv): HBsAg-neg, HBcAb–pos & Pos HBsAb - If HBcAb(+), HBsAb negativity incr risk; - HBsAg(-), HBcAb(+), HBsAb(-) negative= resolved infx, occult infx, chronic hepatitis https://t.co/91ZwqWkdvo https://t.co/c23nN8ER1Y

Links:

Dr. John Cush RheumNow ( View Tweet)
Chemokine CXCL10 a potential biomarker for ILD in systemic sclerosis (SSc)? Study of 165 SSc pts (41 w/ SSc-ILD) found higher serum CXCL10 in SSc-ILD (126 vs. 78.5 pg/ml). Hi levels incr risk of ILD 2.74-fold. Most CXCL10 from inflammed lung tissues https://t.co/Z8pIAZYaC0 https://t.co/ErRsD9Msn1

Links:

Dr. John Cush RheumNow ( View Tweet)
Study from British Columbia, Canada, showed between 2010 & 2020, they saw 31% more new pt rheum consults (149,902); 1st time consults for inflammatory arthritis incr 28% to 51%. While time to 1st visit decr. 35%, time to DMARD initiation was unchanged https://t.co/Et7GzxKeNe https://t.co/2as2YuIV4d

Links:

Dr. John Cush RheumNow ( View Tweet)
National pharmacovigilance database review (1992 to 2021) identified 2217 "Falls", most serious, most in women (61%), & 38% in 18–64 yr olds. Falls attributed to immunomodulators (17%), 24% Fxs & 1 in 7 classified as adverse drug rxns (343) https://t.co/tpUPDc8x09 https://t.co/jdssH7oCjF

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×